Status:
COMPLETED
Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin
Lead Sponsor:
Liuhuaqiao Hospital
Collaborating Sponsors:
Guangdong Province, Department of Science and Technology
Conditions:
Coronary Heart Disease
Eligibility:
MALE
35-65 years
Phase:
PHASE1
Brief Summary
The aim of the study is to investigate the effects of CYP3A polymorphisms on the pharmacokinetics of Atorvastatin in Chinese subjects with coronary heart disease.
Detailed Description
Large variability exists in the individual response to statins. CYP3A polymorphisms likely contribute to variable response to those drugs primarily metabolized by CYP3A including atorvastatin.
Eligibility Criteria
Inclusion
- Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
- Subjects must be \>=35 years and \<=70 years of age.
- Subjects must have an LDL-C concentration \>=2.6 mmol/L and TC concentration \>=4.14 mmol/L
- Body mass index (BMI) must be within the range of 19 to 30 for patients.
- Subjects must have documented coronary heart disease with one or more of the following features:
- Documented stable angina (with evidence of ischemia on exercise testing)
- History of myocardial infarction
- History of percutaneous coronary intervention (with or without stent placement)
- Documented history of unstable angina or non-Q wave myocardial infarction.
Exclusion
- Diabetes and endocrine or metabolic disease.
- Congestive heart failure defined by New York Heart Association (NYHA) as Class III or IV.
- Uncontrolled cardiac arrhythmia.
- Uncontrolled hypertension (Systolic BP \>160 mm Hg and/or Diastolic BP \>100 mmHg on two consecutive measurements).
- Liver or kidney disease confirmed by abnormal lab values or function.
- Smokers who report cigarette use of more then 10 cigarette per day.
- Subjects who consume \>2 alcoholic drinks a day. (A drink is: a can of beer, glass of wine, or single measure of spirits).
- Known human immunodeficiency virus (HIV) positive.
- Cancer.
- Subjects who are on any of the following concomitant medications:
- Medications that are potent inhibitors of CYP3A, including cyclosporine, itraconazole, fluconazole, and ketoconazole, erythromycin or clarithromycin, nefazodone, protease inhibitors,mibefradil and large amounts of grapefruit juice (\>1 quart/day).
- Lipid-lowering agent: niacin (\>200 mg/day) taken within 5 weeks, fibric acid derivatives taken within 8 weeks.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00973986
Start Date
June 1 2009
End Date
March 1 2011
Last Update
November 29 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou General Hospital of Guangzhou Military Command
Guangzhou, Guangdong, China, 510010